Droxidopa Capsule
Product Images NDC 82249-554

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Droxidopa (NDC 82249-554). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civicascript Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Droxi-100 mg-90 Cont (Droxi 100 mg 90 Cont)

Droxi-100 mg-90 Cont (Droxi 100 mg 90 Cont)
Each capsule of this medication contains 100 mg of droxidopa. The usual dosage information can be found in the prescribing information. Store the medication at a temperature range between 20°C to 25°C (68°F to 77°F) with excursions permitted between 5°C to 30°C (41°F to 86°F). The medication should be dispensed in a tight, light-resistant container. There is a warning to keep this medication out of reach of children. For more information, visit the website civicascript.com/droxidopa or scan the provided QR code. The company information includes CivicaScript, LLC and Alkem Laboratories Ltd., with locations in Lehi, Utah, and Mumbai, India. The package contains 90 capsules.*
FDA Label Image

Droxi-200 mg-90 Cont (Droxi 200 mg 90 Cont)

Droxi-200 mg-90 Cont (Droxi 200 mg 90 Cont)
This is a prescription medication with the NDC code 82249-552-90. Each capsule contains 200 mg of droxidopa. It is recommended to store the medication at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The capsules should be kept in a light-resistant container and should not be used if the printed seal under the cap is broken or missing. It is important to keep this medication out of reach of children. This product is distributed by CivicaScript, LLC and manufactured by Alkem Laboratories Ltd., with further information available on www.CivicaScript.com/droxidopa.*
FDA Label Image

Droxi-300 mg-90 Cont (Droxi 300 mg 90 Cont)

Droxi-300 mg-90 Cont (Droxi 300 mg 90 Cont)
This text provides information about Droxidopa capsules, each containing 300 mg of the active ingredient. The usual dosage should be followed as per the prescribing information. The capsules should be stored between 20°C to 25°C but can be exposed to temperatures of 15°C to 30°C. Dispensing should be done in a light-resistant container, and the product should not be used if the seal is broken. The manufacturer is mentioned as CivicaScript, LLC and Alkem Laboratories Ltd. from India. The product label includes details for further information or scanning a QR code for additional resources.*
FDA Label Image

Droxi01 (Droxi01)

Droxi01 (Droxi01)
FDA Label Image

Droxi02 (Droxi02)

Droxi02 (Droxi02)
This text provides information on the baseline value of 5.1 and the units in both groups. It also mentions the mean change in dizziness with Droxidopa being -3.5. Additionally, it refers to the weeks in the double-blind treatment phase.*
FDA Label Image

Droxi03 (Droxi03)

Droxi03 (Droxi03)
The text indicates a comparison between the percentage of subjects who experienced improvement or worsening in OHSA Question 1 when treated with Droxidopa compared to a placebo. It shows that a higher percentage of subjects treated with Droxidopa had improvement while a lesser percentage experienced worsening in comparison to the placebo group.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.